Cannara Biotech to Uplist Shares to Toronto Stock Exchange

The latest announcement is out from Cannara Biotech ( (TSE:LOVE) ).

Cannara Biotech has secured final approval to graduate from the TSX Venture Exchange to the Toronto Stock Exchange, with its common shares set to begin trading on the TSX under the symbol LOVE on March 2, 2026, and a market-opening ceremony scheduled for March 17. The uplisting is expected to improve the company’s market visibility, trading liquidity and access to institutional investors, while TD Cowen’s initiation of research coverage further underscores growing capital markets recognition of the cannabis producer’s evolving position in Canada’s regulated cannabis sector.

The most recent analyst rating on (TSE:LOVE) stock is a Buy with a C$3.25 price target. To see the full list of analyst forecasts on Cannara Biotech stock, see the TSE:LOVE Stock Forecast page.

Spark’s Take on TSE:LOVE Stock

According to Spark, TipRanks’ AI Analyst, TSE:LOVE is a Neutral.

The score is driven primarily by solid financial performance—healthy margins, steady revenue growth, and improving leverage—offset by weaker/less consistent free cash flow. Technicals are mixed with neutral momentum and slight short-term softness, while valuation appears reasonable based on the P/E.

To see Spark’s full report on TSE:LOVE stock, click here.

More about Cannara Biotech

Cannara Biotech Inc. is a vertically integrated producer of affordable premium-grade cannabis and cannabis-derivative products for the Canadian market. The company operates two mega facilities in Québec spanning over 1,600,000 square feet, leveraging low electricity costs to support up to 100,000 kilograms of potential annual cultivation output.

Average Trading Volume: 51,558

Technical Sentiment Signal: Buy

Current Market Cap: C$172.4M

See more data about LOVE stock on TipRanks’ Stock Analysis page.